Skip to main content

SB 5765

In Committee

Senate

Psychiatric pharmacists

Concerning psychiatric pharmacists.

This status may be delayed. See Action History below for the latest updates.

How does a bill become law?
  1. Introduced: The bill is filed and assigned a number.
  2. Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
  3. Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
  4. Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
  5. Governor: The Governor reviews the bill and decides whether to sign or veto it.
  6. Signed: The bill has been signed into law.
Introduced: February 17, 2025
Last Action: January 12, 2026
Status: S Health & Long-

AI Analysis

This analysis was generated by AI and may contain errors. It is not legal advice. Always refer to the official bill text for authoritative information.
People & CommunitiesPeople-leaningCorporate & Wealthy Interests

This bill formally recognizes board-certified psychiatric pharmacists as qualified behavioral health professionals in Washington’s mental health commitment laws, allowing them to evaluate individuals, sign petitions for outpatient treatment, and participate in decisions about involuntary medication. It also updates procedural requirements for assisted outpatient treatment petitions and hearings.

  • Adds a new definition for 'board-certified psychiatric pharmacist'—a pharmacist licensed in Washington who holds a psychiatric pharmacy specialty certification—and includes them in the list of qualified professionals who can evaluate individuals and sign petitions for assisted outpatient treatment.
  • Expands the list of individuals authorized to file petitions for assisted outpatient treatment to include board-certified psychiatric pharmacists alongside physicians, physician assistants, psychiatric advanced registered nurse practitioners, and mental health professionals.
  • Clarifies that psychiatric pharmacists may participate in medical declarations supporting petitions for outpatient treatment, including providing evaluations and cosigned affidavits, and may be involved in authorizing involuntary antipsychotic medication under court-ordered treatment.
  • Requires courts to notify tribes and Indian health care providers when a petition involves an American Indian or Alaska Native person receiving services from a tribe, and gives tribes the right to intervene in the proceedings.
  • Maintains the existing 18-month maximum duration for court-ordered assisted outpatient treatment and preserves the requirement for a care coordinator to develop and submit an individualized treatment plan to the court.

Who is affected

  • People receiving or at risk of involuntary outpatient treatmentIndividuals with serious mental illness or substance use disorders who may be ordered to receive outpatient treatment instead of being hospitalized, especially those with repeated hospitalizations or violent behavior related to their condition.
  • Board-certified psychiatric pharmacistsPharmacists who specialize in psychiatric care and hold board certification; this bill formally recognizes them as qualified professionals who can evaluate patients and sign petitions for outpatient treatment.
  • Behavioral health service providers and treatment facilitiesHospitals, clinics, and behavioral health agencies that provide crisis stabilization, evaluation, and outpatient treatment services; they may be asked to accept responsibility for providing court-ordered less restrictive alternative treatment.
  • Judicial personnelCourts and court staff who must process petitions, hold hearings, and issue orders for assisted outpatient treatment within strict timelines.
Effective: When the contingency in section 26, chapter 433, Laws of 2023 takes effect
Model: Intel/Qwen3-Coder-Next-int4-AutoRoundGenerated: Mar 19, 2026 at 9:17 PM

Pro/Con Analysis

Potential Benefits (2)
  • Formally recognizing board-certified psychiatric pharmacists as qualified professionals expands access to mental health evaluations and treatment petitions, especially in underserved areas where psychiatrist shortages are acute—potentially reducing delays in care and preventing hospitalization for people who might otherwise go without timely intervention.

    HealthcarePeopleRef: Sec. 3(2)(f)
  • Mandating tribal notification and right to intervene in cases involving American Indian/Alaska Native individuals receiving tribal services strengthens tribal sovereignty and ensures culturally appropriate care coordination, improving trust in the behavioral health system and reducing inappropriate or culturally insensitive interventions.

    Local GovernmentPeopleRef: Sec. 3(7)
Potential Concerns (3)
  • Expanding who can file petitions for involuntary outpatient treatment to include board-certified psychiatric pharmacists—without requiring physician oversight—may increase the risk of overuse or misapplication of court-ordered treatment, especially since pharmacists may lack training in differential diagnosis, forensic evaluation, or complex psychosocial context, potentially leading to unwarranted deprivation of liberty for individuals who could be treated voluntarily.

    Rights & LibertiesPeopleRef: Sec. 3(2)(f)
  • Authorizing board-certified psychiatric pharmacists to concur on involuntary antipsychotic medication decisions—without independent physician oversight—risks suboptimal clinical judgment, particularly in complex cases requiring medical evaluation of comorbidities or medication interactions, potentially leading to adverse drug reactions or mismanagement of side effects.

    HealthcareLean peopleRef: Sec. 5(3)
  • The bill allows a single psychiatric pharmacist’s declaration (cosigned only if submitted by a treating mental health professional) to support involuntary treatment, but does not require independent corroboration or peer review—increasing risk of erroneous or biased assessments that could lead to inappropriate detention or forced medication.

    Public SafetyPeopleRef: Sec. 3(5)(b)

Who Is Most Affected

People receiving or at risk of involuntary outpatient treatmentMixed Impact

People with serious mental illness who are at risk of involuntary outpatient treatment may benefit from more timely access to evaluation and treatment by pharmacists, especially in rural or underserved areas—but may also face increased risk of overreach if pharmacists lack training in complex psychosocial assessment or forensic evaluation.

Board-certified psychiatric pharmacistsPositive Impact

Board-certified psychiatric pharmacists gain formal legal authority to evaluate, petition, and cosign treatment plans—expanding their scope of practice and professional recognition, but also exposing them to increased liability and ethical scrutiny in high-stakes legal proceedings.

Behavioral health service providers and treatment facilitiesMixed Impact

Behavioral health providers and treatment facilities may benefit from increased capacity to meet demand for outpatient treatment petitions—but may also face operational strain if pharmacists file petitions without adequate clinical coordination or fail to engage in long-term care planning.

Judicial personnelMixed Impact

Courts and judges gain a new category of qualified petitioners, potentially easing caseload pressure in some jurisdictions—but may face challenges in evaluating the reliability of pharmacist evaluations, especially where pharmacists lack forensic or differential diagnostic training.

Sponsors

Senator Slatter(Democrat)District 48Primary
Senator Nobles(Democrat)District 28Secondary
Senator Trudeau(Democrat)District 27Secondary